WO2005120558A3 - Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease - Google Patents
Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease Download PDFInfo
- Publication number
- WO2005120558A3 WO2005120558A3 PCT/US2005/018471 US2005018471W WO2005120558A3 WO 2005120558 A3 WO2005120558 A3 WO 2005120558A3 US 2005018471 W US2005018471 W US 2005018471W WO 2005120558 A3 WO2005120558 A3 WO 2005120558A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- macroglobulin
- alpha
- methods
- treatment
- cancer
- Prior art date
Links
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 title abstract 4
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 208000035473 Communicable disease Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 title 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57451004P | 2004-05-25 | 2004-05-25 | |
US60/574,510 | 2004-05-25 | ||
US58890204P | 2004-07-16 | 2004-07-16 | |
US60/588,902 | 2004-07-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005120558A2 WO2005120558A2 (en) | 2005-12-22 |
WO2005120558A3 true WO2005120558A3 (en) | 2007-03-29 |
Family
ID=35503661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/018471 WO2005120558A2 (en) | 2004-05-25 | 2005-05-25 | Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005120558A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8968720B2 (en) | 2008-03-20 | 2015-03-03 | University Of Miami | Heat shock protein GP96 vaccination and methods of using same |
US9238064B2 (en) | 2008-03-03 | 2016-01-19 | University Of Miami | Allogeneic cancer cell-based immunotherapy |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4976848B2 (en) | 2003-02-20 | 2012-07-18 | ユニバーシティー オブ コネティカット ヘルス センター | Methods and compositions for the treatment of cancer and infectious diseases using alpha (2) macroglobulin-antigen molecule complexes |
EP2069794A1 (en) * | 2006-10-03 | 2009-06-17 | University of Southern California | Grp78 as a predictor of responsiveness to therapeutic agents |
EA009325B1 (en) * | 2007-03-07 | 2007-12-28 | Петр Генриевич ЛОХОВ | Antitumor vaccine, method for preparing thereof and method for using antitumor immunotherapy |
EA200700940A1 (en) * | 2007-04-27 | 2007-12-28 | Петр Генриевич ЛОХОВ | METHOD FOR OBTAINING ANTITUMENT VACCINE ON THE BASIS OF SURFACE ANTIGENES OF ENDOTHELIAL CELLS |
BR122019024895B8 (en) | 2008-06-26 | 2021-07-27 | Orphazyme As | use of a bioactive agent capable of increasing the intracellular concentration of hsp70 |
CN103338784A (en) | 2010-11-30 | 2013-10-02 | 奥菲泽米有限公司 | Methods for increasing intracellular activity of Hsp70 |
AU2015222917A1 (en) | 2014-02-27 | 2016-09-15 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
JP6728061B2 (en) | 2014-05-05 | 2020-07-22 | リセラ・コーポレイションLycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as RORγ agonists and treatment of diseases |
PL3193840T3 (en) | 2014-09-15 | 2021-12-06 | Orphazyme A/S | Arimoclomol formulation |
EP3292119A4 (en) | 2015-05-05 | 2018-10-03 | Lycera Corporation | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE |
AU2016276947A1 (en) | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
CN109069496A (en) | 2016-04-29 | 2018-12-21 | 奥菲泽米有限公司 | For treating the arimoclomol of glucocerebrosidase related disease |
CN112345661B (en) * | 2020-10-21 | 2022-11-15 | 北京精益捷检测科技有限公司 | Method for determining content of florfenicol in veterinary drug gardenia flaviviridae oral liquid |
NZ800483A (en) | 2020-11-19 | 2024-03-22 | Zevra Denmark As | Processes for preparing arimoclomol citrate and intermediates thereof |
CN114907491B (en) * | 2022-06-21 | 2023-06-16 | 中国科学院西北生态环境资源研究院 | Multi-epitope peptide, helicobacter pylori octavalent multi-epitope vaccine and preparation method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US20030129196A1 (en) * | 2001-08-20 | 2003-07-10 | Srivastava Pramod K. | Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease |
-
2005
- 2005-05-25 WO PCT/US2005/018471 patent/WO2005120558A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US20030129196A1 (en) * | 2001-08-20 | 2003-07-10 | Srivastava Pramod K. | Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9238064B2 (en) | 2008-03-03 | 2016-01-19 | University Of Miami | Allogeneic cancer cell-based immunotherapy |
US8968720B2 (en) | 2008-03-20 | 2015-03-03 | University Of Miami | Heat shock protein GP96 vaccination and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
WO2005120558A2 (en) | 2005-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005120558A3 (en) | Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease | |
WO2003092624A3 (en) | Use of heat shock proteins to enhance efficacy of antibody therapeutics | |
WO2006081826A3 (en) | Survivin peptide vaccine | |
NZ595387A (en) | Peptides for treatment and diagnosis of autoimmune disease | |
WO2001052791A3 (en) | Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents | |
WO2007054279A3 (en) | Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions | |
WO2003090686A3 (en) | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality | |
WO2004064759A3 (en) | Use of tryptanthrin compounds for immune potentiation | |
WO2004010957A3 (en) | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | |
NO20076239L (en) | Peptide conjugate preparations and methods for the prevention and treatment of Alzheimer's disease | |
WO2004005326A3 (en) | Tubulysin conjugates | |
WO2004016750A3 (en) | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
WO2004018649A3 (en) | Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein | |
WO2005055936A3 (en) | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells | |
WO2009062195A3 (en) | Fusion proteins of mannose binding lectins for treatment of disease | |
WO2006027300A3 (en) | Carrier conjugates of gnrh-peptides | |
WO2006137938A3 (en) | Antibody fragments for protection from pathogen infection and methods of use thereof | |
WO2007059931A8 (en) | New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions | |
WO2005007673A3 (en) | Immunogenic peptides | |
WO2006105255A3 (en) | Cancer vaccines and therapeutic methods | |
WO2004074454A3 (en) | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes | |
IL207012A (en) | Pharmaceutical composition comprising sgp28 and a vaccine composition for the treatment of a cancer expressing sgp28 | |
WO2002102318A3 (en) | Eglin c based drugs for treatment of disease | |
EP2277918A3 (en) | Mhc class I and II peptide antigens derived from tumour antigen 5t4 | |
WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |